Previous 10 | Next 10 |
As noted in Wall Street Breakfast "Even when you think China risk is priced, it can get worse" Recent Government actions prompt a new degree of caution in further advices; should we go to the point of taking losses now and adjusting score-keeping to reflect committed errors. Our a...
Zai Lab (ZLAB) and Entasis Therapeutics (ETTX) announce the completion of enrollment in the late-stage trial of sulbactam-durlobactam (SUL-DUR) in patients with confirmed carbapenem-resistant Acinetobacter infections.The company said that it expects to post top-line data readout fro...
– First clinical trial to specifically study confirmed carbapenem-resistant Acinetobacter infections– – Phase 3 top-line data readout now anticipated in early 4Q 2021 – WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE N...
SHANGHAI and SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report financial results and corporate updates for the second quarter ended June 30, 2021 after th...
Like it or not, capital gain prospects for stocks in U.S. equities markets are all directly comparable with one another, and investors who want those gains need to make comparisons. The comparability comes from big-money transaction pressures by competing “Institutional”...
BAMCO’s 13F portfolio value increased marginally from $40.42B to $40.57B this quarter. Ron Baron added TripAdvisor, while increasing Alphabet during the quarter. Their top five positions are at ~24% of the overall portfolio. For further details see: Tracking Ron B...
Cullinan is building a unique hub-and-spoke business model in drug development to build more efficient and scalable pipelines. The company has already built out a pipeline of 7 assets and got the model off the ground to prove that they can structure their pipeline based on opportunist...
Shanghai's Zai Lab announced a four-drug immuno-oncology deal with MacroGenics worth over $1.4 billion. Beijing's LinkDoc Technology, an AI-driven healthcare company based on cancer patient data, filed to IPO on the NASDAQ exchange. Suzhou Innovent Bio has dosed the first person i...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
MacroGenics (MGNX) and Zai Lab (ZLAB) have entered into an exclusive collaboration and license agreement involving up to four immuno-oncology molecules.MacroGenics provides rights to Zai Lab for its DART and TRIDENT multi-specific platforms and a lead research program targeting solid tumors. ...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...